Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa

Risk for thrombotic events with factor IX replacement therapy in patients with haemophilia B remains a concern for patients, those who treat them, and regulatory agencies, based on experience with early use of prothrombin complex concentrates. The current post hoc analysis assessed the incidence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendo, Pablo, Lamb, Janice, Smith, Lynne, Fuiman, Joanne, Korth-Bradley, Joan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794232/
https://www.ncbi.nlm.nih.gov/pubmed/29135476
http://dx.doi.org/10.1097/MBC.0000000000000681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794232/
https://www.ncbi.nlm.nih.gov/pubmed/29135476
http://dx.doi.org/10.1097/MBC.0000000000000681

Ejemplares similares